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Objectives: In this literature review, we concentrate on epidemiology and therapy of osseous echinococcosis, with
an emphasis on the recurrence risk.
Methods: Literature review 1930–2012.
Results: We retrieved 200 publications based upon single case reports or case series, mostly from resource-poor
settings. Among the 721 rural patients (22% females; median age 37 years), 60% of all reported cases were
from the Mediterranean region and almost all patients were immune competent. Echinococcus granulosus was
identified as the most frequent species. Most infections involved a single bone (602/721; 83%) and often the
spine (321 cases; 45%). In eight cases (8/702; 1%), a secondary bacterial surgical site infection was reported.
Surgical intervention was performed in 702 cases (97%), with single intervention in 687 episodes (95%). Complete
excision of the lesion was possible in only 117 episodes (16%). Albendazole was by far the most frequently used
agent in monotherapy with various dosages, while mebendazole in monotherapy was less frequent (32 cases).
The median duration of antihelminthic therapy was 6 months (range 0.7–144 months). There were 124
recurrences (17%) after a median delay of 2 years (range 0.4–17 years). In multivariate analysis, the presence
of visceral organ involvement increased the odds of recurrence by 5.4 (95% CI 3.1–9.4), whereas the number of
surgical interventions, the duration of antihelminthic therapy or the use of hypertonic saline did not influence
recurrence.
Conclusions: Bone echinococcosis is a rare parasitic disease. While treatment modalities vary considerably,
combined surgical and medical approaches are the standard of care with a 17% risk of recurrence.
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Introduction
Echinococcosis is a worldwide zoonosis infecting a large number of
animals and humans.1 – 3 Human bone involvement is often
asymptomatic2,3 and estimated to occur at a frequency of 0.5%4
to 4%2 of all cases of echinococcosis,5,6 most likely by haema-
togenous spread5,6 from the liver or a secondary soft organ
infected from the liver. Endemic regions include rural areas
(sheep farming1,7) of Mediterranean countries, Asia, Africa and
Latin America,8 due to a variety of reasons such as migration,
chronicity of the disease and absence of spontaneous healing.
Nevertheless, a substantial number of physicians and surgeons
in less-endemic rich countries may equally witness bone disease
once in a lifetime.
Other than the consensus for combined aggressive surgical
and medical therapy,9,10 there are no additional detailed
recommendations when confronted with bone hydatid disease.
To the best of our knowledge, there are no systematic reviews
available. Antihelminthic benzimidazole therapy for many years
is frequent.2,10 Some surgeons use bone grafts to fill bone cavities,
while others insert polymethylacrylate.11 Some physicians admin-
ister antimicrobial agents for only 3 months,9,12while others prefer
10 years.5 Overall, recurrences despite several surgical interven-
tions are common.11 In this systematic literature review, we
concentrate on the epidemiology and treatment modalities of
osseous echinococcosis, with an emphasis on the risk of
recurrence.
Methods
We performed a review of the literature from 1930–2012 in the Internet
and PubMed database, using the MeSH terms ‘echinococcus’ or ‘hydatid’
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combined with either ‘bone’, ‘os*’, ‘Knochen*’ or ‘kemik’. Published original
scientific articles in English, French, German, Italian, Spanish, German or
Turkish for human infections were included in an ExcelTM database. Refer-
ences of retrieved articles were further hand-searched for additional
papers, while English language abstracts of articles in other languages
were excluded. In order to avoid doubling of patients, we included only
the last publication from the same author group. Recurrence was defined
as progression of the cyst diameter despite therapy and/or the appearance
of new bone lesions.
Statistical analyses
The majority of articles were case reports or case series. No prospective
cohort studies or randomized trials were found; therefore, a formal
meta-analysis regarding outcomes and treatment modalities was not pos-
sible. Nevertheless, we attempted to evaluate recurrence risks, even if this
approach only considered a collection of retrospective case series. Group
comparisons of categorical variables were performed using the Pearson
x2 or Wilcoxon rank-sum test. A logistic regression analysis determined as-
sociation with the outcome ‘recurrence of bone echinococcosis’. Independ-
ent variables with a P value ≤0.2 in univariate analysis were introduced
stepwise in the multivariate analysis. We included 5–10 outcome events
per predictor variable.13 All variables were checked for confounding and
interaction. P values ≤0.05 (two-tailed) were significant. STATA software
(9.0, STATATM, USA) was used.
Results
Our representative case report
An elderly male Spanish immigrant presented at Geneva University
Hospitals with a chronic intermittent discharge from the right hip.
Twenty-six years previously in rural Spain he was diagnosed with
bone echinococcosis (Echinococcus granulosus) of the femur and
pelvis without visceral involvement. He was treated without
surgery and received albendazole for 2 years. In Switzerland,
after a quiescence of 20 years, he developed chronic bacterial
osteomyelitis of the femurand pelvis due toStaphylococcusepider-
midis, with a productive sinus tract to the skin and an internal
fistula into the abdomen. This bacterial superinfection was new,
whereas the size and number of the cysts did not change over
.20 years. There were no other signs of active echinococcal
disease. Because of the extension of the lesions to weight-bearing
bones, surgical resection was not possible. Suppressive therapy
with oral ciprofloxacin/rifampicin (600 mg three times a day)
stopped the sinus discharge for 2 years, at which time a new intern-
al fistula into the abdomen developed. At present, the patient
receives occasional suppressive antibiotic therapy in cases of
fistula drainage.
Literature review and patients
According to our search criteria, we retrieved 200 publications with
721 different episodes (Table 1). Turkey ranked highest with 158 dif-
ferent reported cases (22%), followed by Spain with 78 cases (9%)
and Germany with 67 reported cases (11%). WHO region 4 (Europe,
Turkey and the former Soviet Union) accounted for almost 60% of
all reported cases. Most publications concerned one single case
(136/200; 68%) and 40 publications between two and nine
cases. Only 24 papers (12%) had a substantial experience with
≥10 episodes. Within the publication window from 1930 to 2012,
half of the manuscripts were published in the last 16 years
(since 1996). The median age of the 721 different patients was
37 years (IQR 29–45 years). Potential immune suppression was
often not addressed, thus the presumption that almost all patients
were immune-competent. In the majority of cases, the proven-
ance of infection could not be established, besides the fact that
the patients lived in rural areas. There were 73 farmers and 6 shep-
herds in the reported cases.
Table 1. Osseous echinococcosis (literature review 1930–2012; 721 episodes)
Number (%) Remarks
Clinical features
male patients 559 (78) rural activities
single bone involvement 602 (83) various sites
spine 321 (45) most dangerous site (paraplegia)
paraplegia 40 (6)
claudication 66 (9) claudication mostly spinal
fractures 48 (7)
substantial pain 292 (40) most patients have pain of varying intensity
soft tissue tumefaction 33 (5)
adjacent soft tissue involvement 114 (16) in vicinity of the bone lesion
concomitant organ involvement 74 (10) also occurring in distant organs
liver 45 (6) most frequently involved organ in general
lung 29 (4)
Treatment
surgery performed 702 (97) no surgery only in inoperable cases
complete excision possible 117 (16)
osteosynthesis and/or grafting 70 (10)
absence of antihelminthic therapy 10 (1) median duration of administration 6 months
Recurrence 124 (17) after a median of 2 years
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Infections, bones and species
Many older publications did not identify the echinococcosis
species. In more recent publications, E. granulosus was identified
asthe most frequent species with only 11 exceptions: 9 monoinfec-
tions due to Echinococcus multilocularis; 1 mixed episode of
E. granulosus and E. multilocularis; and 1 mixture of Echinococcus
vogeli and E. granulosus. Most infections involved a single bone
(602/721; 83%). In 107 episodes, two bones were involved; in 8 epi-
sodes, three bones were involved; and in 4 episodes, four different
bones were involved (Figure 1). In two episodes, echinococcosis
was in contact with arthroplasty material. The median largest
diameter of the bone lesions was 5.5 cm (range 1–20 cm).
Overall, 80% of all cysts were,10 cm in diameter. In 114 episodes,
the parasitic infection involved adjacent soft tissues, together with
distant organs in 74 episodes, including: liver (n¼45), lung (n¼29),
spleen (n¼2), pancreas (n¼2), brain (n¼1), kidney (n¼1), ovaries
(n¼1) and bladder (n¼1).
Surgical treatment
Surgical intervention was performed in almost all cases (702/721;
97%), with the exception of 19 episodes where a surgical approach
was deemed not possible due to potential substantial harm to the
patient. In 687 episodes (95%), there was only one surgical inter-
vention; in seven cases, there were three interventions; in five
cases, there were two interventions; and in three cases, there
were four interventions. Complete excision of the lesion, as best
as could be reported, was possible only in 117 cases (16%), of
which 5 were amputations. The remainder included incomplete
debridement, drainage, laminectomy, arthrodesis and hemipel-
vectomy.14 In 12 operations, the surgeon injected hypertonic
saline at concentrations varying between 3%12 and 40%15 or
ethyl alcohol15 (70%) into the cavity. Very rarely, an anaphylactic
reaction was reported after cavity opening.16 Despite the large dia-
meters of the different lesions and multiple surgical interventions,
a secondary bacterial surgical site infection occurred in only eight
cases (8/702; 1%). The bone cavities became infected with bacter-
ial pathogens in 36 cases (5%), of which 8 were classified as post-
interventional surgical site infections and 28 as spontaneous
superinfections due to various bacteria (staphylococci, Escherichia
coli, Enterobacter spp., Pseudomonas aeruginosa, enterococci and
streptococci).17 The excised cavities were stabilized by osteosynth-
esis in 661 episodes (92%), while fractures occurred in 48 cases.
The time of fracture occurrence was, however, not noted. Hence,
we ignore whether they occurred early or late in the infection
process. In most cases, osteosynthesis was performed with the
use of plates or by spondylodesis; in five cases of femoral infection,
the surgeons performed a total joint arthroplasty.18 Bone grafting
was performed in 30 episodes.
Antimicrobial treatment
Since most publications were found in surgical journals, the main
focus was the surgical approach. Thus, we often lack detailed
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Figure1. Localizations of bone echinococcosis in our literature review 1930–2012. ***One case each of metatarsal and clavicular involvement mentioned
in the literature are not included in our review due to lack of sufficient information.
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information about the modalities of antihelminthic therapy for 427
episodes (59%), especially regarding variations of daily doses
throughout the therapy course. Albendazole (15 mg/kg/day) in
monotherapy was the most frequently used regimen (in a
minimum of 235 episodes).15 Nine cases used albendazole in
reduced doses (10 mg/kg/day) from the start and in 11 cases,
albendazole (15 mg/kg/day) was combined with praziquantel
(40 mg/kg/day). Mebendazole was usually combined with alben-
dazole5 and praziquantel,9 with mebendazole in monotherapy
(10 mg/kg/day) used less frequently (32 cases).5 The remaining
publications indicated ‘benzimidazole therapy’ or ‘albendazole’
without mentioning the dose. In contrast, the duration of antihel-
minthic therapy was almost always noted, with a median duration
of therapyof 6 months (range 0.7–144 months; IQR 3–8 months).
In some cases, the antihelminthic drugs were started 4 weeks prior
to surgery.15 The benzimidazoles were generally well tolerated,
even over a course of 10 years of administration.5
Variables associated with recurrence
Patients were followed for a median of 5.5 years after their last sur-
gical intervention (range 0.1–24 years). Among the 721 episodes,
124 (17%) were reported as recurrent (or progressive infection)
after a median delay of 2 years after treatment for the first
episode (range 0.4–17 years). All recurrences occurred at the
same bone site and there were no new bone lesions at another lo-
cation. Besides clearly evident recurrences (or persistence of infec-
tion), patients with bone echinococcosis reported other sequelae:
persistent pain was very frequent, followed by fractures in 48 epi-
sodes, persistent paraplegia in 14 episodes, handicap in 10 cases,
death due to progressive disease in 5 cases and pseudarthrosis in
1 case. When adjusting for case mix in multivariate analysis, no
single demographic variable was associated with recurrence risk
(Tables 2 and 3), with one exception. The presence of a (visceral)
organ involvement increased the OR for recurrence of bone infec-
tion by 5.4 (95% CI 3.1–9.4), whereas spine involvement was sig-
nificantly associated only in the univariate analysis, but not in the
multivariate analysis. In contrast, among therapeutic aspects, no
variable influenced recurrence risk more than another. The
numberof surgical interventions, the duration of concomitant anti-
helminthic therapy or the injection of hypertonic saline failed to
reveal superiority compared with other regimens (Table 3).
Discussion
Bone echinococcosis is a rare parasitic infection and is difficult to
treat. It is probably associated with very high costs, which is
evident when we extrapolate the massive investment according
to the 200 publications reviewed. It can involve any bone,12 but
has a predilection for the spine, femur and pelvis. Multiosseous
infestation and concomitant soft tissue or organ involvement are
frequent, particularly the combination of proximal femur involve-
ment with the pelvic girdle.2
Geographically, the disease is endemic almost worldwide in
rural areas, especially in sheep farming regions and/or where
there is endemicity of stray dogs.8,18,19 However, there are hot
spots. The Mediterranean region,7,20 – 22 especially Northern
Africa3,7 or Turkey10,11,19,23 – 25 together with a few Asian coun-
tries12 (especially Iran2,26and India14,18),yielded the most publica-
tions, although the disease was also reported in more resource-rich
areas.27 The geographical distribution has probably not changed
since 1930, with many authors finding similar distribution patterns
although with fewer reported cases than in our present review.2
A combined surgical and medical approach seems to be the
basic consensus,9 but there are many flaws when it comes to the
details. Different authors reveal various therapeutic approaches,
especially concerning the duration of antihelminthic therapy com-
bined with surgical excision. The majority of authors performed at
least one surgical intervention together with 6 months of albenda-
zole treatment at oral doses of 15 mg/kg/day.28 A minority pre-
ferred a ‘second surgical look’.6 Similar to surgery for chronic
bacterial osteomyelitis,29,30 the number and type of interventions
did not influence the recurrence risk, even if the approach was
similar to oncologic surgery with margins excised as wide as pos-
sible.3 Filling excised bony defects with polymethylacrylate beads
did not prevent recurrence11 and not even a presumed ‘total
excision’ protected from later recurrence. The proportion of surgical
excision, which was interpreted as ‘total’ during the first surgery,
was only 117/721 episodes (16%), of which 18/117 (15%) recurred.
Total excision of echinococcal cysts is difficult, since many may
have daughter cysts. In addition, the cysts can be substantial in
size or complicated in shape, or even might infest several weight-
bearing bones, as was demonstrated in our own case. Radical
excision in the spine is difficult because of the absence of distinct
anatomic planes and the existence of neural structures.10 The
parasite grows in the direction of least resistance, infiltrating and
damaging the bone like a tumour, with a risk of fracture.7 The
rigid structure of the bone does not allow formation of adventitia.5
Our evaluation suggests that the duration of concomitant anti-
helminthic therapy does not play a role. A duration of,3 months
yielded similar outcomes as compared with administration for
.6 months. Likewise, starting a neoadjuvant regimen with
albendazole15 pre-operatively did not show a benefit in terms of
recurrence. The literature is sparse when it comes to recommenda-
tions for the choice or duration of antimicrobial chemotherapy for
bone echinococcosis. International guidelines exist for visceral
organs such as the liver,31 but not for bone. Albendazole and
Table 2. Clinical variables associated with recurrence of bone
echinococcosis
Recurrence,
n¼124 Pa
No recurrence,
n¼597
Female gender 39 NS 123
Pelvic involvement 13 NS 75
Spine involvement 75 0.019 246
Involvement of.2 bones 9 NS 23
Middle East region 42 0.001 101
Soft tissue involvement 20 NS 94
Organb involvement 35 0.001 39
‘Complete’ surgical excision 18 NS 99
NS, not significant.
aPearson x2 test. Only significant values (P,0.05) are displayed.
bLiver, lung, kidney or pancreas involvement concomitant with bone
infection.
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mebendazole might have the same clinical activity for bone, as
suggested by comparative studies between these two agents in
alveolar echinococcosis.32 However, because of its higher level in
blood plasma, albendazole is regarded by many specialists as the
first choice for bone treatment.8 For visceral organs, a cyclic treat-
ment of benzimidazoles in several 1 month courses separated by
14 day intervals is usual,31 but its efficacy is unknown for bone
infections. To overcome these uncertainties, some authors
suggest depending upon the clinical and serological evolution as
a guide to the duration of antihelminthic therapy,28 although the
dormant state of the remission phase can persist for a long time
and echinococcal serology can remain falsely elevated27 after
treatment.
Despite massive investments of time, resources and surgical
interventions, the long-term local recurrence risk of bone echino-
coccosis was 17%.2,10,12,14,20,26 Local symptomatic recurrences
after 10 years have been reported26 and we often are not con-
cerned whether patients without clinical recurrence are parasito-
logically cured or are in remission with a long-lasting control of
their infection.20 Interestingly, the remission rate and its duration
are similar to the recurrence rate for classic bacterial osteomye-
litis.29,30 This finding is surprising since echinococci, compared
with microscopic bacteria with high reproduction rates, are multi-
cellular parasites that should be removed when performing
surgery. In our formal evaluation, the only variable associated
with local recurrence was distant organ involvement. In the
presence of concomitant bone and visceral organ infestation, the
incidence was five times greater for local bone recurrence or
progression of disease in bone. We were unable to detect any
difference among the visceral organs and could not elucidate if
recurrences were truly local or reinfections from these organs.
Finally, unlike chronic bacterial osteomyelitis in young adults, echi-
nococcal infections appear to be more frequently associated with
fractures or with the need for osteosynthesis after excision. In our
review, 36 of 48 fractures were treated by osteosynthesis and in 30
cases received bone grafts. Of note, the presence of these foreign
materials did not seem to increase long-term recurrence, the
only exception being arthroplasties performed for an unidentified
echinococcal lesion.21,22
Our research has several limitations. (i) Successful cases may
have been reported more frequently than therapeutic failures. On
the other hand, it is likely that difficult-to-treat cases or cases
with particular bone involvement were more often published,
whereas uncomplicated complete surgical resections are not
mentioned. (ii) Physicians and surgeons in resource-rich countries
who rarely see these cases might find them more interesting
than surgeons living in endemic areas. Since there are no national
registries of bone echinococcosis, we ignore the burden of world-
wide disease beneath the ‘tip of the iceberg’. (iii) The literature
search wasbased on the Internet and relied on (Western) European
languages. Even if most publications are written in these
languages, there might be scientific work in local languages invis-
ible on the Internet. (iv) Recurrence for bone hydatid disease not
treated by excision may be difficult to interpret. We used the
Table 3. Logistic regression analysis with outcome ‘recurrence of bone echinococcosis’
Univariate analysis
OR, 95% CI
Multivariate analysis
OR, 95% CI
Variable
female gender 1.4, 0.9–2.2 2.3, 0.7–7.3
age (continuous variable) 1.0, 0.9–1.1 NA
age 35–50 years compared with,35 years 1.0, 0.6–1.8 0.8, 0.3–2.3
age.50 years compared with,35 years 0.7, 0.4–1.1 0.8, 0.3–1.9
pelvic involvement 0.6, 0.3–1.1 0.7, 0.3–1.4
spine involvement 1.7, 1.1–2.6 1.3, 0.8–2.3
cyst diameter (continuous variable) 1.0, 0.8–1.2 NA
more than one bone involved 1.6, 0.7–3.6 NA
soft tissue involvement 1.0, 0.6–1.7 1.1, 0.5–2.8
visceral organ involvement 5.6, 3.1–9.4 5.4, 3.1–9.4
species E. granulosus 1.1, 0.2–5.5 NA
serum CRP value (continuous variable) 0.9, 0.7–1.2 NA
serum eosinophilia.1 G/L 1.1, 0.9–1.3 NA
Treatment modalities
number of surgical interventions 1.0, 0.6–1.8 0.8, 0.3–1.9
presumed total excision 0.9, 0.5–1.5 1.1, 0.6–2.2
bone grafting 0.3, 0.1–1.4 0.4, 0.1–1.7
injection of hypertonic saline 1.4, 0.6–3.0 1.8, 0.2–13.2
duration of antihelminthic therapy 1.0, 0.98–1.01 NA
3–6 months compared with,3 months 0.4, 0.1–1.3 0.3, 0.1–1.1
.6 months compared with,3 months 0.6, 0.3–1.1 0.5, 0.2–1.3
NA, not applicable; CRP, C-reactive protein.
Statistically significant results are shown in bold.
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progression of the cyst cavities or reappearance as defining criteria.
It is theoretically possible that the parasite remains dormant in
once-treated cysts without causing further harm. Whether this
should be classified as persistent infection or remission is a philo-
sophical question. (v) Our attempt to ‘analyse statistically’ 721
published cases may give only an estimate and by no means repre-
sents a valid statistical meta-analysis in proper terms.
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